{"id":"i-n-midazolam","safety":{"commonSideEffects":[{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Drowsiness and sedation"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Amnesia"}]},"_chembl":{"chemblId":"CHEMBL655","moleculeType":"Small molecule","molecularWeight":"325.77"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Midazolam binds to allosteric sites on GABA-A receptors in the central nervous system, increasing the frequency of chloride channel opening and hyperpolarizing neuronal membranes. This potentiation of GABAergic inhibition results in dose-dependent depression of the central nervous system, making it useful for sedation, anxiolysis, and anesthesia induction. The intravenous formulation (I/N refers to intravenous/intranasal administration) allows for rapid onset of action.","oneSentence":"Midazolam is a benzodiazepine that enhances the inhibitory effects of GABA at the GABA-A receptor, producing sedation, anxiolysis, and muscle relaxation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:47.467Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Sedation and anxiolysis prior to diagnostic and therapeutic procedures"},{"name":"Induction of general anesthesia"},{"name":"Acute anxiety and agitation"},{"name":"Seizure management (acute seizures)"}]},"trialDetails":[{"nctId":"NCT06564441","phase":"PHASE1","title":"A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2024-10-01","conditions":"Overweight, Obesity","enrollment":34},{"nctId":"NCT01296555","phase":"PHASE1","title":"A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2011-03-16","conditions":"Solid Cancers, Non-Hodgkin's Lymphoma","enrollment":674},{"nctId":"NCT05011812","phase":"PHASE1","title":"Study of PBI-0451 in Healthy Subjects.","status":"COMPLETED","sponsor":"Pardes Biosciences, Inc.","startDate":"2021-08-14","conditions":"Covid19","enrollment":130},{"nctId":"NCT05334537","phase":"NA","title":"Effect of Aromatherapy on Perioperative Anxiety Level in Cesarean Sections","status":"COMPLETED","sponsor":"Kahramanmaras Sutcu Imam University","startDate":"2020-06-01","conditions":"Anxiety, Midazolam Overdose, Breast Feeding","enrollment":96},{"nctId":"NCT04885075","phase":"PHASE4","title":"Comparing the Efficacy of Intranasal Midazolam Versus Intravenous Diazepam for Control of Seizures in Children","status":"UNKNOWN","sponsor":"Shaheed Zulfiqar Ali Bhutto Medical University","startDate":"2021-05-30","conditions":"Seizures","enrollment":60},{"nctId":"NCT04816344","phase":"","title":"Emergence Delirium in Children for Magnetic Resonance Imaging","status":"COMPLETED","sponsor":"Turkiye Yuksek Ihtisas Education and Research Hospital","startDate":"2018-07-01","conditions":"Delirium, Pediatric Disorder, Anesthesia","enrollment":140},{"nctId":"NCT03333824","phase":"PHASE1","title":"Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-12-01","conditions":"Solid Tumours","enrollment":33},{"nctId":"NCT02127489","phase":"PHASE4","title":"The Effects of Single-dose Rectal Midazolam Application on Post-operative Recovery","status":"COMPLETED","sponsor":"Karadeniz Technical University","startDate":"2005-06","conditions":"Failed Moderate Sedation During Procedure","enrollment":40},{"nctId":"NCT00824057","phase":"PHASE1","title":"Effect of Multiple Doses of AZD6280 on the Pharmacokinetics of Midazolam (CYP3A4) and Caffeine (CYP1A2)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-01","conditions":"Healthy","enrollment":24},{"nctId":"NCT00790114","phase":"PHASE1","title":"Determine the Effect of Multiple Doses of AZD7325, CYP Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-07","conditions":"Healthy Volunteer","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["dormicum"],"phase":"marketed","status":"active","brandName":"I/N Midazolam","genericName":"I/N Midazolam","companyName":"Shaheed Zulfiqar Ali Bhutto Medical University","companyId":"shaheed-zulfiqar-ali-bhutto-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Midazolam is a benzodiazepine that enhances the inhibitory effects of GABA at the GABA-A receptor, producing sedation, anxiolysis, and muscle relaxation. Used for Sedation and anxiolysis prior to diagnostic and therapeutic procedures, Induction of general anesthesia, Acute anxiety and agitation.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}